BIOMAT Database Logo BIOMAT Database Logo

Serum pyruvate kinase in carriers of Duchenne muscular dystrophy. 1977

M F Hardy, and D Gardner-Medwin, and R J Pennington

Five out of 17 carriers of the gene for Duchenne muscular dystrophy had an increased level of serum pyruvate kinase activity, whilst 11, including the same 5, showed an increase in serum creatine kinase.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009136 Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS. Muscular Dystrophy,Myodystrophica,Myodystrophy,Dystrophies, Muscular,Dystrophy, Muscular,Myodystrophicas,Myodystrophies
D011770 Pyruvate Kinase ATP:pyruvate 2-O-phosphotransferase. A phosphotransferase that catalyzes reversibly the phosphorylation of pyruvate to phosphoenolpyruvate in the presence of ATP. It has four isozymes (L, R, M1, and M2). Deficiency of the enzyme results in hemolytic anemia. EC 2.7.1.40. L-Type Pyruvate Kinase,M-Type Pyruvate Kinase,M1-Type Pyruvate Kinase,M2-Type Pyruvate Kinase,Pyruvate Kinase L,R-Type Pyruvate Kinase,L Type Pyruvate Kinase,M Type Pyruvate Kinase,M1 Type Pyruvate Kinase,M2 Type Pyruvate Kinase,Pyruvate Kinase, L-Type,Pyruvate Kinase, M-Type,Pyruvate Kinase, M1-Type,Pyruvate Kinase, M2-Type,Pyruvate Kinase, R-Type,R Type Pyruvate Kinase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum pyruvate-kinase (PK) activity during pregnancy in potential carriers for Duchenne muscular dystrophy.
May 1983, American journal of medical genetics,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum pyruvate kinase in carriers of Duochenne muscular dystrophy.
August 1977, Clinica chimica acta; international journal of clinical chemistry,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum creatine kinase and pyruvate kinase in Duchenne muscular dystrophy carrier detection.
January 1979, Muscle & nerve,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Dilution effect on serum creatine kinase in carriers of Duchenne muscular dystrophy.
January 1979, Annals of clinical biochemistry,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum creatine phosphokinase and pyruvate kinase in neuromuscular disorders and Duchenne dystrophy carriers.
October 1978, Neurology,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Effect of exercise on serum creatine kinase in carriers of Duchenne muscular dystrophy.
February 1982, Journal of medical genetics,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum LDH-5 in carriers of Duchenne muscular dystrophy.
February 1979, Neurology,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Serum pyruvate kinase in different neuromuscular diseases and in carriers of muscular dystrophy.
December 1983, Italian journal of neurological sciences,
M F Hardy, and D Gardner-Medwin, and R J Pennington
Letter: Follow-up study of serum-creatine-kinase in carriers of Duchenne muscular dystrophy.
September 1974, Lancet (London, England),
M F Hardy, and D Gardner-Medwin, and R J Pennington
Duchenne muscular dystrophy manifesting carriers.
June 1989, Archives of neurology,
Copied contents to your clipboard!